1 Min Read
NEW YORK, Dec 16 (Reuters) - BioLine RX Ltd : * U.S.-listed shares up 20.4 percent to $3.07 in premarket after initial phase 2 results of acute myeloid leukemia treatment
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.